Vascular endothelial growth factor in esophageal cancer

Journal of Surgical Oncology

Volumn 87, Issue 2, 2004, Pages 95-104

  Kleespies, Axel ^a   Guba, Markus ^a   Jauch, Karl Walter ^a   Bruns, Christiane J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anti angiogenic therapy; Barrett's disease; Esophagus; Lymphangiogenesis; VEGF; VEGF C

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOZYME; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CISPLATIN; DOCETAXEL; FLUOROURACIL; IMC IC11; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PACLITAXEL; RAPAMYCIN; RECEPTOR ANTIBODY; SEMAXANIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB; INDOLE DERIVATIVE; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; RIBOZYME; VASCULOTROPIN A;

ADENOCARCINOMA; ANGIOGENESIS; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE MARKER; ESOPHAGUS CARCINOMA; HUMAN; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; BIOSYNTHESIS; DRUG ANTAGONISM; ESOPHAGUS TUMOR; LYMPHANGIOGENESIS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; BARRETT ESOPHAGUS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; HUMANS; INDOLES; LYMPHANGIOGENESIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTEIN-TYROSINE KINASES; PYRROLES; RNA, CATALYTIC; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3843150503     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20070     Document Type: Review

References (92)

1. Daly JM, Fry WA, Little AG, et al.: Esophageal cancer: Results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000;190:562-572.
2. AJCC Cancer Staging Handbock. TNM classification of malignant tumors. 6th edition. Heidelberg: Springer; 2002.
3. Roder JD, Busch R, Stein HJ, et al.: Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994;81:410-413.
4. Theunissen PH, Borchard F, Poortvliet DC: Histopathological evaluation of oesophageal carcinoma: The significance of venous invasion. Br J Surg 1991;78:930-932.
5. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
6. Ferrara N: Vascular endothelial growth factor. Eur J Cancer 1996; 32A:2413-2422.
7. Senger DR, Van de WL, Brown LF, et al.: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-324.
8. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20: 4368-4380.
9. Roberts WG, Palade GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369-2379.
10. Nor JE, Christensen J, Mooney DJ, et al.: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999;154:375-384.
11. Tischer E, Mitchell R, Hartman T, et al.: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266:11947-11954.
12. Vincenti V, Cassano C, Rocchi M, et al.: Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996;93:1493-1495.
13. Neufeld G, Cohen T, Gengrinovitch S, et al.: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
14. Shweiki D, Itin A, Soffer D, et al.: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
15. Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000;5:37-44.
16. Kieser A, Weich HA, Brandner G, et al.: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-969.
17. Grugel S, Finkenzeller G, Weindel K, et al.: Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915-25919.
18. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-188.
19. Reinmuth N, Parikh AA, Ahmad SA, et al.: Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 2003;60:199-207.
20. Koide N, Nishio A, Hiraguri M, et al.: Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2001;96:1733-1740.
21. Li Z, Shimada Y, Uchida S, et al.: TGF-alpha as well as VEGF, PD-ECGF, and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000;17:453-460.
22. Millikan KW, Mall JW, Myers JA, et al.: Do angiogenesis and growth factor expression predict prognosis of esophageal cancer? Am Surg 2000;66:401-405.
23. Shih CH, Ozawa S, Ando N, et al.: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6:1161-1168.
24. Koide N, Nishio A, Kono T, et al.: Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus. Hepatogastroenterology 1999;46:952-958.
25. Nagata J, Kijima H, Hatanaka H, et al.: Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med 2002;10:169-172.
26. Ahn MJ, Jang SJ, Park YW, et al.: Clinical prognostic values of vascular endothelial growth factor, microvessel density, and p53 expression in esophageal carcinomas. J Korean Med Sci 2002;17: 201-207.
27. Wallner G, Ciechanski A, Dabrowski A, et al.: Vascular endothelial growth factor and basic fibroblast growth factor in patients with squamous cell oesophageal cancer. Folia Histochem Cytobiol 2001;39:122-123.
28. Sato F, Shimada Y, Watanabe G, et al.: Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 1999;80:1366-1372.
29. Shimada Y, Imamura M, Watanabe G, et al.: Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999;80:1281-1288.
30. Kitadai Y, Haruma K, Tokutomi T, et al.: Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998;4:2195-2200.
31. Uchida S, Shimada Y, Watanabe G, et al.: In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage, and poor prognosis. Br J Cancer 1998;77:1704-1709.
32. Inoue K, Ozeki Y, Suganuma T, et al.: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997;79:206-213.
33. Hironaka S, Hasebe T, Kamijo T, et al.: Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 2002;8:124-130.
34. Shimada H, Takeda A, Nabeya Y, et al.: Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001;92:663-669.
35. McDonnell CO, Harmey JH, Bouchier-Hayes DJ, et al.: Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. Br J Surg 2001; 88:1105-1109.
36. Imdahl A, Bognar G, Schulte-Monting J, et al.: Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002;21:657-663.
37. Rosa AR, Schirmer CC, Gurski RR, et al.: Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis Esophagus 2003;16:112-118.
38. Ogata Y, Fujita H, Yamana H, et al.: Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: Long-term follow-up study. World J Surg 2003;27:584-589.
39. Du JR, Jiang Y, Zhang YM, et al.: Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 2003;9:1604-1606.
40. Mukherjee T, Kumar A, Mathur M, et al.: Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2003;129:430-436.
41. Harrison RF, Perry I, Jankowski JA: Barrett's mucosa: Remodelling by the microenvironment. J Pathol 2000;192:1-3.
42. Couvelard A, Paraf F, Gratio V, et al.: Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000;192:14-18.
43. Auvinen MI, Sihvo EI, Ruohtula T, et al.: Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002;20:2971-2979.
44. Baatar D, Jones MK, Tsugawa K, et al.: Esophageal ulceration triggers expression of hypoxia-inducible factor-1 alpha and activates vascular endothelial growth factor gene: Implications for angiogenesis and ulcer healing. Am J Pathol 2002;161:1449-1457.
45. Lord RV, Park JM, Wickramasinghe K, et al.: Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003;125:246-253.
46. Torres C, Wang H, Turner J, et al.: Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma. Hum Pathol 1999;30:753-758.
47. Folkman J, Watson K, Ingber D, et al.: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-61.
48. Duque JL, Loughlin KR, Adam RM, et al.: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523-527.
49. Weingartner K, Ben Sasson SA, Stewart R, et al.: Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: An in vitro model for assessment. J Urol 1998;159:465-470.
50. Nguyen M, Watanabe H, Budson AE, et al.: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86:356-361.
51. Li VW, Folkerth RD, Watanabe H, et al.: Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994;344:82-86.
52. Yeo KT, Wang HH, Nagy JA, et al.: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 1993;53:2912-2918.
53. O'Reilly MS, Holmgren L, Shing Y, et al.: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
54. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
55. Kraft A, Weindel K, Ochs A, et al.: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-187.
56. Mohle R, Green D, Moore MA, et al.: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997;94:663-668.
57. Banks RE, Forbes MA, Kinsey SE, et al.: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-964.
58. Yamamoto Y, Toi M, Kondo S, et al.: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996;2:821-826.
59. Kondo S, Asano M, Matsuo K, et al.: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994;1221:211-214.
60. Fujisaki K, Mitsuyama K, Toyonaga A, et al.: Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998;93:249-252.
61. Salven P, Ruotsalainen T, Mattson K, et al.: High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998;79:144-146.
62. Salven P, Teerenhovi L, Joensuu H: A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90:3167-3172.
63. Kumar H, Heer K, Lee PW, et al.: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279-1285.
64. Hefler L, Tempfer C, Obermair A, et al.: Serum concentrations of vascular endothelial growth factor in vulvar cancer. Clin Cancer Res 1999;5:2806-2809.
65. Dirix LY, Vermeulen PB, Hubens G, et al.: Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996; 7:843-848.
66. Linder C, Linder S, Munck-Wikland E, et al.: Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998;18:2063-2068.
67. Lewis CE, Leek R, Harris A, et al.: Cytokine regulation of angiogenesis in breast cancer: The role of tumor-associated macrophages. J Leukoc Biol 1995;57:747-751.
68. Berse B, Brown LF, Van de WL, et al.: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992;3:211-220.
69. Sheid B: Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett 1992;62:153-158.
70. Spence GM, McAllister I, Graham AN, et al.: Effect of multimodality therapy on ciculating vascular endothelial growth factor levels in patients with oesophagal cancer. Br J Surg 2002;89:495-496.
71. Verheul HM, Hoekman K, Lupu F, et al.: Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000;6:166-171.
72. Spence GM, Graham AN, Mulholland K, et al.: Vascular endothelial growth factor levels in serum and plasma following esophageal cancer resection-relationship to platelet count. Int J Biol Markers 2002;17:119-124.
73. Maniwa Y, Okada M, Ishii N, et al.: Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998;114: 1668-1675.
74. O'sullivan GC, Sheehan D, Clarke A, et al.: Micrometastases in esophagogastric cancer: High detection rate in resected rib segments. Gastroenterology 1999;116:543-548.
75. Vogel SB, Mendenhall WM, Sombeck MD, et al.: Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995;221:685-693.
76. Ohtsu A, Yoshida S, Boku N, et al.: Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol 1995;25:261-266.
77. Coia LR: Chemoradiation as primary management of esophageal cancer. Semin Oncol 1994;21:483-492.
78. Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467.
79. Rockwell S, Moulder JE: Hypoxic fractions of human tumors xenografted into mice: A review. Int J Radiat Oncol Biol Phys 1990;19:197-202.
80. Moulder JE, Rockwell S: Tumor hypoxia: Its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313-341.
81. Suit HD, Suchato C: Hyperbaric oxygen and radiotherapy of a fibrosarcoma and of a squamous-cell carcinoma of C3H mice. Radiology 1967;89:713-719.
82. Tanigawa N, Matsumura M, Amaya H, et al.: Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer 1997;79:220-225.
83. Koukourakis MI: Tumour angiogenesis and response to radiotherapy. Anticancer Res 2001;21:4285-4300.
84. Boucher Y, Leunig M, Jain RK: Tumor angiogenesis and interstitial hypertension. Cancer Res 1996;56:4264-4266.
85. Shimada H, Hoshino T, Okazumi S, et al.: Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002; 86:552-557.
86. Kukk E, Lymboussaki A, Taira S, et al.: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996;122:3829-3837.
87. Kaipainen A, Korhonen J, Mustonen T, et al.: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92:3566-3570.
88. Dumont DJ, Jussila L, Taipale J, et al.: Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998;282: 946-949.
89. Noguchi T, Takeno S, Shibata T, et al.: VEGF-C expression correlates with histological differentiation and metastasis in squamous cell carcinoma of the esophagus. Oncol Rep 2002;9:995-999.
90. Kitadai Y, Amioka T, Haruma K, et al.: Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001; 93:662-666.
91. Gu ZP, Wang YJ, Li JG, et al.: VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma. World J Gastroenterol 2002;8:44-48.
92. Guo WZ, Ran YL, Liu J, et al.: [Enhancement by hypoxia of antisense VEGF(165) gene expression in esophageal cancer cells]. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002;34:625-629.